Adherence to Cardiovascular Disease Medications: Does Patient-Provider Race/Ethnicity and Language Concordance Matter? by Traylor, Ana H. et al.
Adherence to Cardiovascular Disease Medications:
Does Patient-Provider Race/Ethnicity and Language
Concordance Matter?
Ana H. Traylor, MPP1,2, Julie A. Schmittdiel, PhD3, Connie S. Uratsu, BA3,
Carol M. Mangione, MD, MSPH4, and Usha Subramanian, MD, MS5,6
1Goldman School of Public Policy, University of California, Berkeley, CA, USA; 2Care Management Institute, Kaiser Permanente, Oakland, CA,
USA; 3Division of Research, Kaiser Permanente Medical Care Program, Northern California, Oakland, CA; 4Los Angeles School of Medicine
and Public Health, University of California, Berkeley, CA, USA; 5Roudebush VAMC, Indianapolis, IN, USA; 6Division of General Internal Medicine
and Geriatrics, Department of Medicine, Regenstrief Institute for Healthcare, Inc., Indianapolis, IN, USA.
BACKGROUND: Patient–physician race/ethnicity and
language concordance may improve medication adher-
ence and reduce disparities in cardiovascular disease
(CVD) by fostering trust and improved patient–physi-
cian communication.
OBJECTIVE: To examine the association of patient
race/ethnicity and language and patient–physician
race/ethnicity and language concordance on medica-
tion adherence rates for a large cohort of diabetes
patients in an integrated delivery system.
DESIGN:We studied 131,277 adult diabetes patients in
Kaiser Permanente Northern California in 2005. Probit
models assessed the effect of patient and physician
race/ethnicity and language on adherence to CVD
medications, after controlling for patient and physician
characteristics.
RESULTS: Ten percent of African American, 11 % of
Hispanic, 63% of Asian, and 47% of white patients had
same race/ethnicity physicians. 24%of Spanish-speaking
patients were linguistically concordant with their physi-
cians. African American (46%), Hispanic (49%) and Asian
(52%) patients were significantly less likely than white
patients (58%) to be in good adherence to all of their CVD
medications (p<0.001). Spanish-speaking patients were
less likely than English speaking patients to be in good
adherence (51% versus 57%, p<0.001). Race concordance
for African American patients was associated with adher-
ence to all their CVD medications (53% vs. 50%, p<0.05).
Language concordance was associated with medication
adherence for Spanish-speaking patients (51% vs. 45%,
p<0.05).
CONCLUSION: Increasing opportunities for patient–
physician race/ethnicity and language concordance
may improve medication adherence for African Ameri-
can and Spanish-speaking patients, though a similar
effect was not observed for Asian patients or English-
proficient Hispanic patients.
KEY WORDS: diabetes; racial/ethnic and linguistic health disparities;
medication adherence; cardiovascular risk factor control; race/ethnic
and language concordance; racial/ethnic minority health; medical
workforce diversity.
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INTRODUCTION
Cardiovascular disease is the leading cause of death in the
United States, and patients with diabetes are at a higher risk of
CVD deaths and events than the general population1. African
American, Hispanic, Native American and some Asian popula-
tions are more likely to die or have a CVD-related event than
the white population, even after controlling for socioeconomic
status and insurance coverage2.
Appropriate use ofmedications to reduce CVD risk factors has
been shown to lower CVD risk factor levels and reduce CVD
related deaths and events for patients with diabetes3. Adherence
to medications for chronic diseases such as diabetes, hyperten-
sion and hyperlipidemia is a challenge for all patients, regardless
of patient race. Approximately 10–30% of persons with type 2
diabetes have been reported to withdraw from prescribed regi-
mens within one year of diagnosis,4 and long-term persistence in
use of lipid-lowering and anti-hypertensive therapies is low5–7.
Barriers to the patient–physician relationship such as physi-
cian stereotypes and bias and disparities in the quality of
interpersonal care may create even greater obstacles to medica-
tion adherence for patients of color8–10. Patients of color are
more likely to face language barriers and miscommunication
with their providers8 and have also have shorter and less patient
centered office visits than white patients.10 Patients of color are
also more likely to be negatively perceived by their physicians.
Patient race is associated with physicians’ assessment of patient
intelligence, feelings of affiliation toward the patient, and beliefs
about the patients’ likelihood of risk behavior and adherence
with medical advice11.
Patients are more likely to utilize services and adhere to
medical advice and pharmacological regimens if they trust the
health care system, feel affiliation with their providers and if
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their providers communicate effectively with them.12–14 Poten-
tially as a response to the barriers noted above, African
American and Hispanic patients are less likely to trust the
medical system and more likely than whites to perceive they
would have received better medical care if they belonged to a
different racial and ethnic group. Patients of color are also more
likely to believe that medical staff judged them unfairly or treated
them with disrespect based on race and ethnicity15–19.
Physicians from racial and ethnic minority backgrounds may
possess culturally specific knowledge, skills and experience that
reduce barriers to the patient–physician relationship for racial/
ethnic and linguistic minority patients.20–22 Race, ethnicity and
language concordance are thought to foster trust, communica-
tion and better patient-provider interaction.8,19 For example,
race/ethnicity concordance is associated with higher patient
ratings of physicians’ participatory decision-making and higher
patient satisfaction.8,23 Compared to patients whose primary
physicians are of a different race/ethnicity, patients who are of
the same racial or ethnic group as their physicians are more
likely to use needed health services, are less likely to postpone or
delay seeking care and report a higher volume of use of health
services.24,25 Other studies have found that language concor-
dance and interpreter use positively affects patients’ perceived
understanding of their disease and is positively associated with
a range of health comes26,27.
Few empirical studies have examined or found an association
between race, ethnicity or language concordance andmedication
adherence.28 The purpose of this study is to examine the
association between patient race/ethnicity, patient language
and patient–physician race/ethnicity and language concordance
on CVD risk factor medication adherence for patients with
diabetes.
METHODS
Study Population
The study population consisted of a cohort of African American,
Hispanic, Asian and white adult diabetes patients in Kaiser
Permanente’s Northern California (KPNC) Diabetes Registry who
were identified as having diabetes prior to January 1, 2005 and
were continuously enrolled with an active drug benefit through-
out 200529. Study participants were further assessed for hyper-
tension and hyperlipidemia using KP automated clinical
databases (See Appendix for definitions of diabetes, hyperten-
sion and hyperlipidemia). Patient demographic and clinical data
was obtained through membership and clinical databases.
Patient self-reported race/ethnicity and language preference
was obtained from KP member surveys, study surveys and
hospitalization data and was available for 87% of patients.
Physician self-reported race/ethnicity and language data was
obtained from physician demographic files and was available for
93.5% of physicians. The final study population consisted of
131,277 African American, Asian, White and Hispanic adult
diabetes patients and 1750 physicians. Patients with missing
racial/ethnic data were excluded from the analysis.
KP Northern California members comprise approximately
25% of the adult population between 20–79 years old in Northern
California and are similar in age and gender to both the insured
anduninsurednonKPpopulation. Compared tonon-KP insured,
KP members are less likely to be white but similar in other
characteristics. Compared to non-insured Northern Califor-
nians, KP members are more likely to be white and less likely to
be very low income or to have very low levels of education.30
Dependent Variables
Treatment adherence for CVD risk factor controllingmedications
(diabetes, cholesterol and hypertension medications) was calcu-
lated with KP prescription databases using continuous multiple
interval measures of gaps in therapy (CMG).31 CMG is the
proportion of days a patient was prescribed medication and did
not have the medication available. For each individual condition
(hyperglycemia, hypertension and hyperlipidemia), CMG was
first calculated separately for eachmedication class filled at least
twice in the 12 months prior to the last date when above target
levels were observed in 2005. Individual class adherence was
then combined into a single measure for all medications
prescribed for a single condition, weighting the estimate for each
medication class by the number of days from the first to last fill in
the 12 month period. Medications filled only once were not
included in the analysis because CMG can not be calculated
from single fills. Because many prior studies have found
significant clinical effects when cumulative days of refill gaps
equal or exceed 20%,31 we defined good adherence for each
condition as a non-adherencemeasure less than 20%. Individual
condition adherence was then combined into a single measure of
adherence for all medication classes a patient was prescribed for
diabetes, hypertension and/or hyperlipidemia. Patients who had
80% of their medications available for each condition for which
they were being treated were coded as 1. Patients who had less
than 80% of their medications available for any condition were
coded as 0.
Main Explanatory Variables
Self-reported patient race/ethnicity was the main explanatory
variable for multivariable models that assessed predictors of
medication adherence with white patients as the reference group.
Patient–physician race/ethnicity concordance was defined as the
patient and primary care provider/physician being from the same
racial/ethnic background. The patients’ primary care provider was
defined as the physician linked to the patient the most months in
2005. It is important to note that linguistic, national background,
immigrant status, acculturation and cultural diversity exists
within each racial and ethnic category. We were unable to assess
concordance beyond broad racial/ethnic categories.
Patient preferred language was obtained through patient self-
report. Three percent of patients in the study report a preferred
language other than English. Of these patients the majority
prefer Spanish (55%) followed by Cantonese (12%). Patients from
other language backgrounds made up the remaining 33% of
patients with primary language other than English. Patient–
physician Spanish language concordance was defined as the
patient reporting Spanish as the preferred language spoken and
the physician reporting Spanish language fluency. Physician
language proficiency was obtained through physician self-report
at the onset of employment with the medical group. Because less
than 1% of African American and less than 2% of white patients
report a primary language other than English, our Spanish
language analyses focus on Hispanic patients (23% of Hispanic
patients report Spanish as their primary language). Due to
language diversity and small sample sizes within language
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subgroups for Asian patients, we were unable to conduct a
language concordance analysis for Asian patients.
Multivariate Analyses
Probit models were constructed to assess the marginal effect of
patient race on adherence to CVD medications (hypoglycemic,
lipid lowering, and anti-hypertensive medications). Probit analy-
ses, stratified by patient race/ethnicity, examined the effect of
race/ethnicity concordance on medication adherence to all CVD
medications and for each condition. All models adjusted for
patient clusteringwithin physicianpanels. From thesemodelswe
calculated the predictedpercentage of patients in goodadherence
by patient race/ethnicity, patient preferred language and pa-
tient–physician race/ethnicity and language concordance. All
models controlled for patient demographics (age, gender, lan-
guage, and U.S census 2000 geocoded education and income) as
well as measures of health status and utilization (number of
comorbid conditions, number of primary care visits in 2005,
Medicare status, and number of medication classes across the
three conditions). The models also controlled for physician age,
gender, language proficiency, panel size and number of diabetic
patients in panel as fixed effects. All analyses were performed
using STATA version 10. This study was developed and approved
by the Steering Committee of the Translating Research in Action
for Diabetes (TRIAD) Study, and approved by the KPNC Institu-
tional Review Board.
RESULTS
Patient and Physician Characteristics
Most patients in the sample (94%) were being treated for more
than one CVD risk factor and almost three-quarters of patients
(72%) were being treated for all three conditions (diabetes, high
cholesterol, and hypertension). Almost half of the patients
(46%) were White, 16% Asian, 11% Hispanic and 10% were
African American. Almost 97% of patients reported speaking at
least some English. Spanish was the preferred language of
almost a quarter (23%) of Hispanic patients. Physicians were
disproportionately White (47%) or Asian (40%). Less than 8%
of physicians were either African American or Hispanic. While
almost a quarter of physicians (23%) reported proficiency in a
non-English language, less than 5% of physicians spoke
Spanish. African American and white patients had longer
relationships with their physicians (6.3 years for African
American and 6.1 for white patients) than Asian and Hispanic
patients (5.9 for Asian and 5.6 for Hispanic patients). Spanish-
speaking patients had the shortest relationship with their
physicians (4.5 years). (Table 1)
Concordance by Patient Race/Ethnicity
and Language
Asian patients were most likely to be race concordant with
their providers (63%), followed by white patients (47%),
Hispanic patients (11%), and African American (9.7%)
patients. Twenty-four percent of Spanish-speaking patients
were linguistically concordant with their physicians.
Medication Adherence by Patient Race/Ethnicity
and Language
After adjusting for patient and physician characteristics,
African American, Hispanic and Asian patients were signifi-
cantly less likely than white patients to be good adherence to
all of their CVD risk factor controlling medications (Table 2).
Spanish-speaking patients were less likely than English
speaking patients to be in good adherence (51% versus 57%,
p<0.001). The results of analyses that examined adherence for
each condition/risk factor separately were significant and in
the same direction as our combined measure of adherence to
CVD medications.
Table 1. Patient Characteristics by Patient Race/Ethnicity
Patient Demographic
Characteristics
African
American
n=15,905 (%)
Hispanic
n=17,750 (%)
White
n=74,900 (%)
Asian
N=22,722 (%)
Preferred
language
is Spanish
N=6,712 (%)
P-value*
Age (Mean) 60.8 60.1 63.8 60.1 56.8 (<0.001)
Male 45 50 52.6 49.2 50.9 (<0.001)
Female 55 50 47.4 50.8 49.1 (<0.001)
English not primary language 0.7 22 1.5 10.2 100 (<0.001)
Median household income (Geocoded)** $50,371 $55,956 $61,712 $68,016 $51,709 (<0.001)
% College Degree in census block (Geocoded)* ** 15.3 15 19.5 21.7 (<0.001)
Physician Race
African American 9.7 3.4 3.3 2.2 3.2 (<0.001)
Hispanic 3.7 11.2 4.4 2.5 25.3 (<0.001)
White 40.4 35.6 47.4 31.5 34.9 (<0.001)
Asian 44 46.3 41.7 63.2 36.1 (<0.001)
Health Status Variables
# of visits (Mean) 6.4 6.2 6.3 5.3 5.7 (<0.001)
# of years with physician 6.3 years 5.6 years 6.1 years 5.9 years 4.5 years (<0.001)
# Comorbid conditions (Mean) 2.7 2.5 2.8 2.4 2.2 (<0.001)
Pill burden (Total number of drug classes) 8.3 7.4 8.2 7.6 5.9 (<0.001)
*P-values represent the significance of one-way ANOVA or chi-square tests of group differences
**Median household income variable is the geocoded median household income for the population over 25 years old in the census block where a patient lives
***Geocoded education is the percent of the population over 25 years old with a college degree in the census block where a patient lives
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Medication Adherence by Race/Ethnicity
and Language Concordance
After adjusting for patient and physician characteristics, race/
ethnicity concordance for African American patients was
marginally associated with good combined adherence to all
risk factor medications for which a patient was being treated
(53 vs. 50, p<0.05) (Table 3). Language concordance was
associated with improved medication adherence for Hispanic
patients (51% vs. 45%, p-value<0.05). Race/ethnicity concor-
dance was not significantly associated with adherence to CVD
medications for white, Asian or Hispanic patients. While in the
same direction, these results were insignificant when each
condition/risk factor was assessed separately.
DISCUSSION
Patient race/ethnicity and language were significant predictors
of adherence to CVD risk factor medications for patients in this
study. African American, Hispanic and Asian patients were
less likely to adhere to CVD medications than white patients.
Multiple factors may explain these disparities including differ-
ences in attitudes and beliefs about medication,32 differences
in socioeconomic status that might influence affordability of
drug regimens,33 differences in interpersonal care that may
influence patient behavior,8–10 language and communication
barriers11 and different levels of trust in physicians and/or the
health care system.19,34 However, it is interesting to note that
even in a managed care system with similar drug benefits,
racial disparities in adherence to medications remain, suggest-
ing that factors beyond socio-economic status play a very
important role in medication adherence for chronic illness.
Patient–physician race/ethnicity concordance was not sig-
nificantly associated with adherence for white patients. Given
that white patients are less likely to face cultural and language
barriers in the medical system, this finding is not surprising.
Contrary to the race/ethnicity concordance hypothesis, how-
ever, Hispanic and Asian concordance were also not associated
with good adherence. This too is not entirely surprising, given
the diversity within all racial and ethnic groups, and particu-
larly within the Hispanic and Asian populations. Primary
language spoken, dialect, level of acculturation and cultural
differences among patients from different national back-
grounds within each racial and ethnic group may mask
concordance effects.
Our findings on language concordance suggest that lan-
guage concordance influences medication adherence, but we
cannot ascertain whether concordance effects occur because
Table 3. Adjusted Adherence to CVD Medications by Patient Race/Ethnicity and Language Concordance
Black Patients
% (p-value)
Hispanic Patients
% (p-value)
Asian Patients
% (p-value)
White Patients
% (p-value)
Spanish-Speaking
Patients % (p-value)
Black PCP Non-black
PCP
Hispanic
PCP
Non-Hispanic
PCP
Asian PCP Non-Asian
PCP
White PCP Non-white
PCP
Spanish
Proficient
PCP
Non-Spanish
PCP
Glucose
Controlling
Medications
79.8
(0.166)
77.6 76.1
(0.655)
76.6 82.7
(0.131)
81.6 85.3
(0.550)
85.1 77.5
(0.430)
76.6
Lipid
Lowering
Medications
79.6
(0.331)
78 78
(0.492)
77.3 80.1
(0.947)
80.1 84.1
(0.301)
83.7 80.5
(0.157)
77.5
BP lowering
Medications
76.6
(0.98)
76.6 77
(0.262)
78.8 82
(0.570)
81.7 83.6
(0.081)
82.9 81
(0.423)
79.3
All CVD
Medications
53.2
(0.044)
49.8 50.7
(0.262)
52.5 59.9
(0.092)
58.4 61.8
(.428)
61.4 50.6
(0.026)
44.8
Adjusted percentages based on stratified probit model results, with discordant patients as the reference category. Model adjusted for patient age, gender,
preferred language, number of comorbidities, # of primary care visits in 2005, Medicare status, # of medication classes taken for condition, pill burden,
geocoded education and income, physician age, gender, race, language, panel size and # of diabetic patients in panel. Patient–physician Spanish
language concordance was defined as the patient reporting Spanish as the primary language spoken and the physician reporting Spanish language
fluency.
Table 2. Adjusted Adherence to CVD Medications by Patient Race
Black Patients %
(p-value)
Hispanic Patients %
(p-value)
Asian Patients %
(p-value)
White Patients %
(p-value)
Spanish-speaking
Patients % (p-value)
Glucose lowering
medications
74.2 (<.001) 75 (<0.001) 77.1 (<0.001) 82 (reference) 76 (<0.001)
Lipid Lowering
Medications
75 (<0.001) 75.2 (<0.001) 77 (<0.001) 81.3 (reference) 77.3 (<0.001)
BP lowering
Medications
74.4 (<0.001) 77.4 (<0.001) 78.5 (<0.001) 81.7 (reference) 78.7 (<0.001)
All CVD Medications 46 (<0.001) 49.4 (<0.001) 52.2 (<0.001) 57.8 (reference) 50.7 (<0.001)
All adjusted analyses significant at the p<0.001 level
Models adjusted for patient age, gender, preferred language, number of comorbidities, # of primary care visits in 2005, Medicare status, # of medication
classes taken for condition, pill burden, geocoded education and income, physician age, gender, race, language, panel size and # of diabetic patients in
panel
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of better patient–physician communication and reduced lan-
guage barriers or because language may be a proxy for the
patients’ level of acculturation. It is possible that less accul-
turated patients are more likely to benefit from concordance.
Our results suggest a modest association between race/
ethnicity concordance and treatment adherence for African
American patients. Race/ethnicity concordance for African
American patients was significantly associated with improved
adherence to CVD medications. A long history of discrimina-
tion, legal and de facto segregation in the United States health
care system, infamous medical trials (e.g. The Tuskegee
Syphilis trials) and under-representation of racial and ethnic
minority groups in health care professions present unique
challenges to the patient–physician relationship for African
American patients.16,34 African American patients, then, may
be more likely to benefit from racially concordant patient-
provider relationships, insofar as these relationships alleviate
barriers to the patient–physician relationship.
While this study is the first to examine the association of
race/ethnicity and language concordance with adherence to
cardiovascular medications for a large cohort of patients with
diabetes, a few limitations of the study should be noted. First,
as an observational study, we were unable to randomly assign
patients to treatment and control groups. Unobserved factors
correlated with adherence may have influenced the selection of
a same race, ethnicity or language physician. Second, while
race/ethnicity may be an approximate proxy for cultural
concordance, a great deal of diversity exists within each
racial/ethnic and linguistic group. Third, patients and physi-
cians were from a single large, integrated healthcare delivery
system; it is possible that patients and physicians in this
setting may be different from patients and physicians in other
settings. Based on previous research comparing insured and
uninsured patients33, we hypothesize that patients in this
study were less likely to be very low income or have very low
levels of education. Adherence and the impact of concordance
may very well differ in the more general population.
Although we adjusted for a comprehensive set of variables,
we were limited by the fact that we only had access to socio-
economic status indicators from geo-coding; individual-level
data on education and income were not available in this study.
Our language variable was limited in that we have no measure
for English proficiency. We also have no direct measure of
health literacy, immigrant status and level of acculturation, all
potentially important predictors of medication adherence.
Another potential concern is that our measurement of adher-
ence does not include adherence to other treatment recom-
mendations, such as diet, exercise and other lifestyle changes.
In addition, patients with diabetes receive care from several
health professionals (e.g. pharmacists, nutritionists, nurse
practitioners, etc). We were unable to assess patient concor-
dance with medical staff and these relationships may have
played a role in predicting adherence. We hypothesize that we
underestimate the impact of concordance because patients in
this system are seen by several physicians, depending on their
particular needs.
CONCLUSION
Race/ethnicity and language concordance were modestly
associated with improved medication adherence for African
American and Spanish-speaking Hispanic patients, suggesting
that efforts to improve opportunities for concordance such as
race/ethnicity based recruitment and retention efforts could
reduce disparities in medication adherence. Reducing medica-
tion adherence disparities can ultimately improve health out-
comes and reduce disparities for African American and
Spanish-speaking Hispanic patients. Future research to ex-
amine the particular aspects of the concordant patient–
physician relationship that make a difference can inform
efforts to reduce disparities in medication management.
By increasing the opportunity for race/ethnicity and lan-
guage concordance for patients for whom concordance would
make a difference, efforts to diversify the medical workforce
can have an important impact on public health.
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APPENDIX. DIAGNOSTIC CRITERIA FOR DIABETES
MELLITUS, HYPERTENSION, AND DYSLIPIDEMIA
Diabetes Mellitus (one of the following):
1) At least one prescription of insulin or an oral hypoglycemic
agent; or
2) At least two outpatient diagnoses of diabetes mellitus; or
3) One outpatient diagnosis of diabetes mellitus plus > 1 Hb
A1c>7 %; or
4) At least one hospital discharge with a primary DM-related
diagnosis (ICD-9 code 250.X).
Hypertension (one of the following):
1) At least one prescription for an anti-hypertensive medica-
tion plus an outpatient diagnosis of hypertension; or
2) At least two outpatient diagnoses of hypertension; or
3) At least one prescription for an anti-hypertensive medica-
tion plus one or more elevated outpatient blood pressure
readings (> 130 mm Hg systolic, or>85 mm Hg diastolic);
or
4) At least one outpatient diagnosis of hypertension plus at
least one blood pressure reading of >130 mm Hg systolic or
>85 mm Hg diastolic;
Dyslipidemia (one of the following):
1) At least one prescription for an anti-lipemic agent; or
2) Outpatient diagnosis of hyperlipidemia/hypercholesterol-
emia with an LDL-cholesterol value > 100; or
3) Outpatient diagnosis of hyperlipidemia/hypercholesterol-
emia with a prior LDL-cholesterol value > 100 (within
2 years prior to 7/01/00).
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